Literature DB >> 20955455

Modulation of exogenous antibiotic activity by host cathelicidin LL-37.

Katarzyna Leszczyńska1, Andrzej Namiot, Paul A Janmey, Robert Bucki.   

Abstract

The increasing number of infections caused by drug-resistant bacteria has spurred efforts to develop new therapeutic strategies. When applied locally, exogenous antibiotics work in an environment rich in endogenous antibacterial molecules such as the cathelicidin peptide LL-37, which has increased expression at infection sites because of the stimulatory effects of bacterial wall products on neutrophils and other cell types. To test for possible additive effects of exogenous and endogenous antibacterial agents, we evaluated the minimal inhibitory concentration (MIC) to assess the antibacterial activity of amoxicillin with clavulanic acid (AMC), tetracycline (T), erythromycin (E) and amikacin (AN) against different clinical isolates of Staphyloccocus aureus in combination with synthetic LL-37. These studies revealed that the antibacterial activity of AMC was strongly potentiated when added in combination with LL-37. However, in the presence of LL-37, we did not observe any decrease in the MIC values of T and E, particularly against methicillin-resistant S. aureus and macrolide-lincosamide-streptogramin B (MLS(B))(+)/β-lactamase (+) strains, indicating a lack of synergistic action between these molecules. Interaction between exogenous antibiotics and host antibacterial molecules should be considered to provide optimal treatment, especially in cases of topical infections accompanied by increasing expression of host antibacterial molecules.
© 2010 The Authors. Journal Compilation © 2010 APMIS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20955455      PMCID: PMC3386844          DOI: 10.1111/j.1600-0463.2010.02667.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  24 in total

Review 1.  Peptide antimicrobial agents.

Authors:  Håvard Jenssen; Pamela Hamill; Robert E W Hancock
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

2.  Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure.

Authors:  Renat Shaykhiev; Christoph Beisswenger; Kerstin Kändler; Judith Senske; Annette Püchner; Thomas Damm; Jürgen Behr; Robert Bals
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2005-06-17       Impact factor: 5.464

3.  Release of the antimicrobial peptide LL-37 from DNA/F-actin bundles in cystic fibrosis sputum.

Authors:  R Bucki; F J Byfield; P A Janmey
Journal:  Eur Respir J       Date:  2007-01-10       Impact factor: 16.671

4.  LL-37 protects rats against lethal sepsis caused by gram-negative bacteria.

Authors:  Oscar Cirioni; Andrea Giacometti; Roberto Ghiselli; Cristina Bergnach; Fiorenza Orlando; Carmela Silvestri; Federico Mocchegiani; Alberto Licci; Barbara Skerlavaj; Marco Rocchi; Vittorio Saba; Margherita Zanetti; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

5.  Synergistic actions of antibacterial neutrophil defensins and cathelicidins.

Authors:  I Nagaoka; S Hirota; S Yomogida; A Ohwada; M Hirata
Journal:  Inflamm Res       Date:  2000-02       Impact factor: 4.575

6.  Synergistic and additive killing by antimicrobial factors found in human airway surface liquid.

Authors:  P K Singh; B F Tack; P B McCray; M J Welsh
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2000-11       Impact factor: 5.464

Review 7.  Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients.

Authors:  M H Kollef
Journal:  Clin Infect Dis       Date:  2000-09       Impact factor: 9.079

8.  Human host defense peptide LL-37 prevents bacterial biofilm formation.

Authors:  Joerg Overhage; Andrea Campisano; Manjeet Bains; Ellen C W Torfs; Bernd H A Rehm; Robert E W Hancock
Journal:  Infect Immun       Date:  2008-06-30       Impact factor: 3.441

9.  Increased resistance to cationic antimicrobial peptide LL-37 in methicillin-resistant strains of Staphylococcus aureus.

Authors:  Kazuhisa Ouhara; Hitoshi Komatsuzawa; Toshihisa Kawai; Hiromi Nishi; Tamaki Fujiwara; Yoshihiro Fujiue; Masao Kuwabara; Koji Sayama; Koji Hashimoto; Motoyuki Sugai
Journal:  J Antimicrob Chemother       Date:  2008-03-26       Impact factor: 5.790

Review 10.  The roles of cathelicidin LL-37 in immune defences and novel clinical applications.

Authors:  Anastasia Nijnik; Robert E W Hancock
Journal:  Curr Opin Hematol       Date:  2009-01       Impact factor: 3.284

View more
  9 in total

1.  The cysteine protease ApdS from Streptococcus suis promotes evasion of innate immune defenses by cleaving the antimicrobial peptide cathelicidin LL-37.

Authors:  Fang Xie; Yanan Zan; Yueling Zhang; Ning Zheng; Qiulong Yan; Wanjiang Zhang; Huihui Zhang; Mingjie Jin; Fuguang Chen; Xinyuan Zhang; Siguo Liu
Journal:  J Biol Chem       Date:  2019-10-16       Impact factor: 5.157

2.  Bioactivity of WLBU2 peptide antibiotic in combination with bioerodible polymer.

Authors:  J R McClanahan; R Peyyala; R Mahajan; R C Montelaro; K F Novak; D A Puleo
Journal:  Int J Antimicrob Agents       Date:  2011-09-15       Impact factor: 5.283

Review 3.  Nanomaterials-Based Combinatorial Therapy as a Strategy to Combat Antibiotic Resistance.

Authors:  Angel León-Buitimea; Cesar R Garza-Cárdenas; María Fernanda Román-García; César Agustín Ramírez-Díaz; Martha Ulloa-Ramírez; José Rubén Morones-Ramírez
Journal:  Antibiotics (Basel)       Date:  2022-06-12

4.  Antibacterial activity of the human host defence peptide LL-37 and selected synthetic cationic lipids against bacteria associated with oral and upper respiratory tract infections.

Authors:  Katarzyna Leszczynska; Dorota Namiot; Fitzroy J Byfield; Katrina Cruz; Malgorzata Zendzian-Piotrowska; David E Fein; Paul B Savage; Scott Diamond; Christopher A McCulloch; Paul A Janmey; Robert Bucki
Journal:  J Antimicrob Chemother       Date:  2012-11-07       Impact factor: 5.790

Review 5.  Nanomedicine as an emerging approach against intracellular pathogens.

Authors:  Andrea L Armstead; Bingyun Li
Journal:  Int J Nanomedicine       Date:  2011-12-09

Review 6.  Recent advances in Staphylococcus aureus infection: focus on vaccine development.

Authors:  Shamshul Ansari; Rajesh Kumar Jha; Shyam Kumar Mishra; Birendra Raj Tiwari; Ahmed Morad Asaad
Journal:  Infect Drug Resist       Date:  2019-05-13       Impact factor: 4.003

7.  Combinatory Therapy Antimicrobial Peptide-Antibiotic to Minimize the Ongoing Rise of Resistance.

Authors:  Luis R Pizzolato-Cezar; Nancy M Okuda-Shinagawa; M Teresa Machini
Journal:  Front Microbiol       Date:  2019-08-09       Impact factor: 5.640

Review 8.  The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent.

Authors:  Kylen E Ridyard; Joerg Overhage
Journal:  Antibiotics (Basel)       Date:  2021-05-29

9.  Combination of alpha-melanocyte stimulating hormone with conventional antibiotics against methicillin resistant Staphylococcus aureus.

Authors:  Madhuri Singh; Ravisekhar Gadepalli; Benu Dhawan; Kasturi Mukhopadhyay
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.